Longbow Finance’s Vertex Pharmaceuticals VRTX Stock Holding History

Longbow Finance’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-18,686	Closed	-$9.06M	–	99
2025 Q1	$9.06M	Sell	18,686 -4,013	-18%	-$1.87M	1.09%	27
2024 Q4	$9.14M	Buy	22,699 +16,028	+240%	+$7.43M	1%	27
2024 Q3	$3.1M	Sell	6,671 -7,954	-54%	-$3.82M	0.33%	66
2024 Q2	$6.86M	Sell	14,625 -878	-6%	-$381K	0.71%	34
2024 Q1	$6.48M	Sell	15,503 -40,991	-73%	-$17.3M	0.66%	41
2023 Q4	$23M	Buy	56,494 +2,605	+5%	+$962K	2.33%	8
2023 Q3	$18.7M	Buy	53,889 +12,433	+30%	+$4.35M	2.25%	11
2023 Q2	$14.6M	Sell	41,456 -25	-0.1%	-$8.42K	1.7%	19
2023 Q1	$13.1M	Buy	41,481 +418	+1%	+$125K	1.65%	21
2022 Q4	$11.9M	Buy	+41,063	New	+$12.5M	1.6%	26

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Longbow Finance's VRTX Position: Q2 2025 in Review

Longbow Finance sold out of Vertex Pharmaceuticals (VRTX) in Q2 2025, closing a stake of 18,686 shares — an estimated $9.06M sold.

Longbow Finance first reported a position in VRTX in Q4 2022 and held it in 10 quarters. The position peaked at $23M in Q4 2023. 1,562 funds tracked by Wall St. Rank hold VRTX as of Q2 2025.

Longbow Finance reported no remaining Vertex Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Longbow Finance sold 18,686 Vertex Pharmaceuticals shares in Q2 2025, an estimated $9.06M.
Longbow Finance first reported a position in Vertex Pharmaceuticals in Q4 2022 and held it in 10 quarters.
Longbow Finance's Vertex Pharmaceuticals position peaked at $23M in Q4 2023.
1,562 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2025.

Based on Longbow Finance's 13F filing for Q2 2025, filed 5 Aug 2025.